{"<h3>Importance</h3>": [0], "Colorectal": [1, 51], "cancer": [2, 11, 28, 52, 60], "(CRC)": [3], "is": [4, 53, 116, 165], "the": [5, 54, 67, 138, 148, 154, 170, 177, 192, 217, 235, 266, 291, 324, 330, 334], "third": [6, 55], "most": [7, 56], "common": [8, 57], "cause": [9, 58], "of": [10, 31, 59, 88, 153, 179, 221, 273, 306, 320, 333], "mortality": [12, 61], "worldwide": [13], "with": [14, 43, 70, 80, 181, 200, 212, 245, 268, 301], "more": [15, 344, 357], "than": [16, 102], "1.85": [17], "million": [18], "cases": [19], "and": [20, 38, 64, 100, 131, 150, 187, 247, 296, 314, 361], "850": [21], "000": [22], "deaths": [23, 73], "annually.": [24], "Of": [25], "new": [26], "colorectal": [27, 82], "diagnoses,": [29], "20%": [30, 103], "patients": [32, 89, 180, 222, 345, 358], "have": [33, 142], "metastatic": [34, 81, 114, 182, 321], "disease": [35, 45], "at": [36, 278], "presentation": [37], "another": [39], "25%": [40], "who": [41], "present": [42], "localized": [44], "will": [46], "later": [47], "develop": [48], "metastases.": [49], "<h3>Observations</h3>": [50], "for": [62, 112, 216, 260, 336], "men": [63], "women": [65], "in": [66, 75, 137, 198, 290, 309, 317], "United": [68], "States,": [69], "53": [71], "200": [72], "projected": [74], "2020.": [76], "Among": [77], "people": [78], "diagnosed": [79], "cancer,": [83], "approximately": [84], "70%": [85], "to": [86, 95, 126, 147, 161, 191, 208, 219, 237, 253, 257, 326, 329, 365], "75%": [87], "survive": [90], "beyond": [91, 97, 104], "1": [92], "year,": [93], "30%": [94], "35%": [96, 218], "3": [98], "years,": [99], "fewer": [101, 362], "5": [105, 140], "years": [106, 141], "from": [107, 367], "diagnosis.": [108], "The": [109], "primary": [110], "treatment": [111, 146, 299, 353], "unresectable": [113], "CRC": [115, 183, 322], "systemic": [117], "therapy": [118, 122, 244], "(cytotoxic": [119], "chemotherapy,": [120, 201], "biologic": [121, 331], "such": [123], "as": [124], "antibodies": [125, 190], "cellular": [127], "growth": [128, 194], "factors,": [129], "immunotherapy,": [130], "their": [132], "combinations.)": [133], "Clinical": [134], "trials": [135], "completed": [136], "past": [139], "demonstrated": [143], "that": [144, 172, 356], "tailoring": [145], "molecular": [149, 318], "pathologic": [151], "features": [152, 332], "tumor": [155, 335], "improves": [156], "overall": [157, 251, 304], "survival.": [158, 349], "Genomic": [159, 350], "profiling": [160, 319, 351], "detect": [162], "somatic": [163], "variants": [164], "important": [166], "because": [167], "it": [168], "identifies": [169], "treatments": [171, 328], "may": [173, 287], "be": [174, 288], "effective.": [175], "For": [176, 234, 265], "50%": [178], "with<i>KRAS/NRAS/BRAF</i>wild-type": [184], "tumors,": [185], "cetuximab": [186], "panitumumab": [188], "(monoclonal": [189], "epithelial": [193], "factor": [195], "receptor": [196], "[EGFR]),": [197], "combination": [199, 243], "can": [202, 346], "extend": [203], "median": [204, 303], "survival": [205, 252, 305], "by": [206], "2": [207], "4": [209], "months": [210, 259, 308], "compared": [211, 256], "chemotherapy": [213], "alone.": [214], "However,": [215], "40%": [220], "with<i>KRAS</i>or<i>NRAS</i>sequence": [223], "variations": [224], "(formerly": [225], "termed<i>mutations</i>),": [226], "effective": [227], "targeted": [228, 242], "therapies": [229], "are": [230, 363], "not": [231], "yet": [232], "available.": [233], "5%": [236, 267], "10%": [238], "with<i>BRAF": [239], "V600E</i>sequence": [240], "variations,": [241], "BRAF": [246], "EGFR": [248], "inhibitors": [249], "extended": [250, 348], "9.3": [254], "months,": [255], "5.9": [258], "those": [261], "receiving": [262], "standard": [263], "chemotherapy.": [264], "microsatellite": [269], "instability": [270], "(the": [271], "presence": [272], "numerous": [274], "insertions": [275], "or": [276, 282, 293], "deletions": [277], "repetitive": [279], "DNA": [280], "units)": [281], "mismatch": [283], "repair": [284], "deficiency,": [285], "immunotherapy": [286], "used": [289], "first": [292], "subsequent": [294], "line": [295], "has": [297], "improved": [298], "outcomes": [300], "a": [302], "31.4": [307], "previously": [310], "treated": [311], "patients.": [312], "<h3>Conclusions": [313], "Relevance</h3>": [315], "Advances": [316], "facilitate": [323], "ability": [325], "direct": [327], "specific": [337], "patient": [338], "subsets.": [339], "Although": [340], "cures": [341], "remain": [342], "uncommon,": [343], "anticipate": [347], "allows": [352], "selection": [354], "so": [355], "derive": [359], "benefit": [360], "exposed": [364], "toxicity": [366], "ineffective": [368], "therapies.": [369]}